Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.

Abstract

The efficacy of telavancin, a bactericidal lipoglycopeptide, was compared to that of vancomycin and linezolid against methicillin-resistant Staphylococcus aureus (MRSA) in a murine pneumonia model. Telavancin produced greater reductions in lung bacterial titer and mortality than did vancomycin and linezolid at human doses equivalent to those described by the area under the concentration-time curve. These results suggest the potential utility of telavancin for treatment of MRSA pneumonia.

• Authors: Noe Reyes, Robert Skinner, Koné Kaniga, Kevin M Krause, Josephine Shelton, Glenmar P Obedencio, Alexander Gough, Michael Conner, Sharath S Hegde
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 49 Issue 10 Pg. 4344-6 (Oct 2005) ISSN: 0066-4804 [Print] United States
• PMID: 16189117 (Publication Type: Journal Article)

Chemical References

• Aminoglycosides
• Anti-Infective Agents
• Glycopeptides
• Lipoglycopeptides
• telavancin

Topics

• Aminoglycosides (administration & dosage, chemistry, pharmacokinetics, therapeutic use)
• Animals
• Anti-Infective Agents (administration & dosage, chemistry, pharmacokinetics, therapeutic use)
• Drug Resistance, Bacterial
• Female
• Glycopeptides (therapeutic use)
• Lipoglycopeptides
• Methicillin Resistance
• Mice
• Mice, Inbred BALB C
• Microbial Sensitivity Tests
• Neutropenia (drug therapy, microbiology)
• Pneumonia, Staphylococcal (drug therapy)
• Staphylococcal Infections (drug therapy, microbiology)
• Staphylococcus aureus (drug effects)